|1.||Qian, Xuhong: 6 articles (06/2013 - 03/2010)|
|2.||Xu, Yufang: 6 articles (06/2013 - 03/2010)|
|3.||Liu, Jianwen: 6 articles (06/2013 - 03/2010)|
|4.||Allen, Steven L: 3 articles (04/2015 - 04/2010)|
|5.||Lundberg, Ante S: 3 articles (04/2015 - 04/2010)|
|6.||Shen, Ke: 3 articles (06/2013 - 10/2012)|
|7.||Li, Qi: 3 articles (06/2013 - 02/2013)|
|8.||Liang, Xin: 3 articles (04/2013 - 03/2010)|
|9.||Zhao, Jin: 3 articles (10/2012 - 07/2009)|
|10.||Zhang, Huanying: 2 articles (06/2013 - 03/2010)|
03/25/2010 - "The majority of compounds 7a-d and 8a-d potently inhibited the growth of the five tested cancer cell lines with IC(50) values ranging from 2 to 10 microM and are more active than amonafide, a naphthalimide that was in phase III clinical trials. "
06/01/1998 - "A phase II trial of amonafide in patients with mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study."
02/01/1992 - "The Southwest Oncology Group conducted a Phase II study of amonafide in patients with metastatic or recurrent squamous cell cervical cancer. "
02/01/1992 - "Evaluation of amonafide in cervical cancer, phase II. A SWOG study."
12/01/1987 - "The recommended dose of amonafide for phase II studies in solid tumors is 400 mg/m2/day X 5 for good-risk and 300-320 mg/m2/day X 5 days for poor-risk patients with courses repeated at 21-28-day intervals."
12/01/2010 - "B1, a novel amonafide analogue, overcomes the resistance conferred by Bcl-2 in human promyelocytic leukemia HL60 cells."
11/01/1987 - "Two of the primary metabolites, the N(N5)-acetyl and N'(N1)-oxide metabolites of Amonafide, were tested in vitro for cytotoxicity against P388 murine leukemia cells. "
03/01/1995 - "Seventy-three patients enrolled onto three Cancer and Leukemia Group B (CALGB) phase II trials of amonafide (300 mg/m2 daily for 5 days) were studied, using a limited sampling strategy (45 minutes and 24 hours) to estimate the amonafide area under the plasma concentration-time curve (AUC). "
03/01/1995 - "Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study."
02/15/1987 - "In vitro cloning data suggest that nafidimide may be a therapeutic option for patients with leukemia resistant to m-AMSA."
|3.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
04/01/1991 - "Phase II trial of amonafide in patients with stage III and IV non-small-cell lung cancer."
04/01/1991 - "With the low response rate and the toxicity observed, amonafide at this dosage and schedule has limited use in the treatment of non-small-cell lung cancer."
04/01/1991 - "Sixteen patients with stage III or IV non-small-cell lung cancer who had not previously received chemotherapy were given amonafide at an initial dose of 300 mg/m2 i.v. daily for 5 days every 21 days. "
05/01/1993 - "In an effort to identify new active chemotherapeutic agents against non-small cell lung cancer (NSCLC), the authors conducted a randomized Phase II trial to evaluate the efficacy of amonafide or trimetrexate in patients with Stage IV disease. "
05/01/1993 - "A randomized phase II trial of amonafide or trimetrexate in patients with advanced non-small cell lung cancer. "
01/01/1994 - "Based on the results of this study, amonafide showed no activity against gastric adenocarcinoma; however toxicity appeared acceptable at the 300 mg/m2/d x 5 consecutive days every 3 weeks dose and schedule."
01/01/1994 - "Phase II study of amonafide in gastric adenocarcinoma. "
11/01/1991 - "Phase II study of amonafide in advanced pancreatic adenocarcinoma."
06/15/1994 - "Advanced colorectal adenocarcinoma: treatment with amonafide."
11/01/1991 - "To determine the efficacy of amonafide in patients with advanced, measurable pancreatic adenocarcinoma, 15 patients previously untreated with chemotherapy were entered on a phase II trial. "
03/01/1995 - "Further analysis of interracial differences demonstrated that minority women had slower clearance of amonafide (P = .026) and a higher incidence of grade 4 leukopenia (P = .042). "
02/01/1996 - "The goal of this study was to construct and validate a pharmacodynamic model-based dosing strategy for amonafide, to try to further decrease inter-patient variability in leukopenia. "
12/01/1991 - "Leukopenia was the dose-limiting toxicity; though it was generally modest with the 800 mg/m2 amonafide starting dose, an initial dose reduction should be considered in patients with prior radiotherapy and/or bone marrow involvement. "
08/01/1994 - "For illustration, a pharmacodynamic model for leukopenia was constructed by stepwise linear regression from data of 41 patients with cancer treated with the drug amonafide. "
01/01/1995 - "The cause of death was attributed to amonafide in one patients (from sepsis) and to teniposide in two patients (due to infection and leukopenia). "
|1.||trioctyl phosphine oxide (TOPO)
|3.||DNA (Deoxyribonucleic Acid)
|5.||malic acid (malate)
|7.||Etoposide (VP 16)
|9.||Idarubicin (4 Demethoxydaunorubicin)
|1.||Drug Therapy (Chemotherapy)
|4.||Heterologous Transplantation (Xenotransplantation)